ZFIN ID: ZDB-FISH-150901-23930
Fish name: i114Tg
Genotype: i114Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by i114Tg
Human Disease Conditions Citations
fungal infectious disease fungal treatment by injection: Mucor circinelloides Inglesfield et al., 2018
gastrointestinal system disease chemical treatment by environment: dextran sulfate Oehlers et al., 2017
chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Oehlers et al., 2017
GENE EXPRESSION
Gene expression in i114Tg
RNA expression
Expressed Gene Structure Conditions Figures
cd36 standard conditions Fig. 5 from Fink et al., 2015
cxcl8a chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
transection: caudal fin Fig. 1 from de Oliveira et al., 2015
Fig. 4 from Ogryzko et al., 2014
cxcl8b.1 chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
viral treatment by exposure to environment: Carp sprivivirus Fig. 1 from de Oliveira et al., 2015
defbl1 control Fig. 3 with image from Galindo-Villegas et al., 2012
germ free Fig. 3 with image from Galindo-Villegas et al., 2012
gbp4 control Fig. 1 from Tyrkalska et al., 2016
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
il1b control Fig. 1 from Tyrkalska et al., 2016
Fig. 3 with image from Galindo-Villegas et al., 2012
germ free Fig. 1 from Tyrkalska et al., 2016
Fig. 1 with imageFig. 4 from Ogryzko et al., 2014
Fig. 3 with image from Galindo-Villegas et al., 2012
irf4a standard conditions Fig. 1 with image from Wang et al., 2015
lcp1 standard conditions Fig. 1 from Renshaw et al., 2006
lyz standard conditions Fig. 1 with image from Wang et al., 2015
mpeg1.1 standard conditions Fig. 1 from Benard et al., 2015
mpeg1.2 standard conditions Fig. 1 from Benard et al., 2015
mpx standard conditions Fig. 5 from Fink et al., 2015
Fig. 1 from Renshaw et al., 2006
nfil3 standard conditions Fig. 1 from Progatzky et al., 2012
ptgs2b transection: caudal fin Fig. 4 from Ogryzko et al., 2014
caiap bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab2-lcp1 physical alteration: anatomical structure Fig. 6 from Varela et al., 2014
Fig. 1 with image from Jones et al., 2013
Ab1-lcp1 control Fig. 4 from Kanwal et al., 2013
Ab1-nitrotyrosine chemical treatment: pharmaceutical Fig. 4 with image from Elks et al., 2014
Ab1-nitrotyrosine bacterial treatment Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 4 with imageFig. 5 with image from Elks et al., 2014
Fig. 3 with imageFig. 7 from Elks et al., 2013
Ab1-gnb control Fig. 2 with image from Ke et al., 2017
Ab1-nitrotyrosine standard conditions Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 4 with imageFig. 5 with image from Elks et al., 2014
Fig. 3 with imageFig. 7 from Elks et al., 2013
Ab-2F11 control Fig. 3 from Lorent et al., 2015
Ab2-nos standard conditions Fig. 1 with image from Elks et al., 2014
Fig. 5 with image from Elks et al., 2013
Ab2-nos bacterial treatment Fig. 1 with image from Elks et al., 2014
Ab2-lcp1 standard conditions Fig. 6 from Varela et al., 2014
Fig. S1 with image from Jones et al., 2013
Ab-2F11 chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
Ab1-gnb1a control Fig. 2 with image from Ke et al., 2017
Ab4-GFP GFP control Fig. 2 with image from Hedrera et al., 2013
Reporter gene expression
Expressed Gene Structure Conditions Figures
DsRed amputation: caudal fin Fig. 1Fig. 3Fig. 4 from de Oliveira et al., 2015
EGFP standard conditions Fig. S8 with image from Tyrkalska et al., 2016
Fig. 4 from Stachura et al., 2013
transection: caudal fin Fig. 6 with image from Robertson et al., 2016
GFP standard conditions 49 figures with image from 30 publications
chemical treatment: pharmaceutical 11 figures with image from 9 publications
bacterial treatment 49 figures with image from 24 publications
PHENOTYPE
Phenotype in i114Tg
Phenotype Conditions Figures
acute inflammatory response increased occurrence, abnormal chemical treatment: copper(II) sulfate Fig. 3 with image from Gallardo et al., 2015
gall bladder morphology, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
gill neutrophil amount, ameliorated chemical treatment: environmental contaminant Fig. 4 from Progatzky et al., 2016
gill neutrophil decreased amount, abnormal chemical treatment: environmental contaminant Fig. 3Fig. 4 from Progatzky et al., 2016
heart leukocyte activation increased occurrence, abnormal chemical treatment by environment: isoprenaline Fig. 6 from Kossack et al., 2017
heart neutrophil increased amount, abnormal chemical treatment by environment: isoprenaline Fig. 6 from Kossack et al., 2017
hindbrain macrophage decreased amount, abnormal fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone Fig. 2 from Inglesfield et al., 2018
hindbrain neutrophil decreased amount, abnormal fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone Fig. 2 from Inglesfield et al., 2018
hindbrain neutrophil increased amount, abnormal fungal treatment by injection: Mucor circinelloides Fig. 2 with image from Voelz et al., 2015
intestine anatomical region has extra parts of type neutrophil, abnormal bacterial treatment: Escherichia coli O157:H7 Fig. 3 with image from Stones et al., 2017
intestine neutrophil amount, ameliorated chemical treatment by diet: glycoprotein, protein content Fig. 1 with image from Ulloa et al., 2016
intestine neutrophil amount, ameliorated chemical treatment by environment: cabergoline, chemical treatment by environment: dextran sulfate Fig. 2 from Oehlers et al., 2017
intestine neutrophil amount, ameliorated chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid, chemical treatment by environment: cabergoline Fig. 2 from Oehlers et al., 2017
intestine neutrophil amount, ameliorated chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid, chemical treatment by environment: sincalide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by environment: dextran sulfate, chemical treatment by environment: sincalide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by environment: dextran sulfate Fig. 2Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 1Fig. 2Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, abnormal chemical treatment by diet: glycoprotein, protein content Fig. 1 with image from Ulloa et al., 2016
intestine neutrophil increased amount, exacerbated chemical treatment by environment: haloperidol, chemical treatment by environment: dextran sulfate Fig. 2 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: lorglumide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: dextran sulfate, chemical treatment by environment: devazepide Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: devazepide, chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 3 from Oehlers et al., 2017
intestine neutrophil increased amount, exacerbated chemical treatment by environment: lorglumide, chemical treatment by environment: dextran sulfate, chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 3 from Oehlers et al., 2017
leukocyte il1b expression amount, ameliorated transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 4 from Ogryzko et al., 2014
leukocyte il1b expression amount, ameliorated transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 4 from Ogryzko et al., 2014
leukocyte il1b expression increased amount, abnormal transection: caudal fin Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal transection: caudal fin Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal transection: caudal fin Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 4 from Ogryzko et al., 2014
leukocyte protein nitrosylation increased process quality, abnormal bacterial treatment Fig. 3 with imageFig. 7 from Elks et al., 2013
leukocyte migration involved in inflammatory response process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 3Fig. 5Fig. 6 from Burgon et al., 2014
leukocyte migration involved in inflammatory response process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 6 from Burgon et al., 2014
leukocyte migration involved in inflammatory response process quality, abnormal physical alteration: caudal fin, chemical treatment: pharmaceutical Fig. 7 from de Oliveira et al., 2013
macrophage accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
macrophage decreased amount, abnormal viral treatment: Carp sprivivirus Fig. 6 from Varela et al., 2014
neutrophil accumulation swim bladder, abnormal fungal treatment by injection: Mucor circinelloides Fig. 5 with image from Voelz et al., 2015
neutrophil accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
neutrophil amount, normal bacterial treatment by exposure to environment: Pseudomonas aeruginosa Fig. 1 with image from Díaz-Pascual et al., 2017
neutrophil decreased amount, abnormal bacterial treatment by injection: Burkholderia cenocepacia Fig. 3 with image from Mesureur et al., 2017
neutrophil decreased speed, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 6 from Burgon et al., 2014
neutrophil decreased speed, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 4Fig. 6 from Burgon et al., 2014
neutrophil caiap expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Escherichia coli DH5[alpha] Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Burkholderia stabilis Fig. 3 with image from Mesureur et al., 2017
neutrophil increased amount, abnormal fungal treatment by injection: Mucor circinelloides Fig. 1 from Inglesfield et al., 2018
neutrophil il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
neutrophil increased amount, abnormal chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 1 from Oehlers et al., 2017
neutrophil increased amount, abnormal bacterial treatment by injection: Burkholderia cenocepacia Fig. 7 with image from Mesureur et al., 2017
neutrophil normal amount, normal chemical treatment: pharmaceutical Fig. 3 with image from Herbst et al., 2015
neutrophil apoptotic process increased process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 3 from Burgon et al., 2014
neutrophil apoptotic process increased occurrence, abnormal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 3 with image from Hoodless et al., 2016
neutrophil apoptotic process occurrence, normal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 3 with image from Hoodless et al., 2016
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: SB220025, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: anthra[1,9-cd]pyrazol-6(2H)-one, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: 2-(2-amino-3-methoxyphenyl)chromen-4-one, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: wortmannin, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: PP2, amputation: caudal fin Fig. 4 from de Oliveira et al., 2015
neutrophil chemotaxis decreased occurrence, abnormal transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist Fig. 2 from Ogryzko et al., 2014
neutrophil chemotaxis decreased occurrence, abnormal transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 2 from Ogryzko et al., 2014
neutrophil chemotaxis decreased occurrence, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil chemotaxis decreased process quality, abnormal amputation: caudal fin, chemical treatment: dibenziodolium chloride Fig. 2 from de Oliveira et al., 2014
neutrophil chemotaxis decreased process quality, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil chemotaxis increased occurrence, abnormal bacterial treatment: Escherichia coli O157:H7 Fig. 3 with image from Stones et al., 2017
neutrophil chemotaxis increased occurrence, abnormal bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil chemotaxis increased occurrence, abnormal bacterial treatment by injection: Escherichia coli DH5[alpha] Fig. 3 with image from Díaz-Pascual et al., 2017
neutrophil mediated killing of fungus process quality, normal fungal treatment by injection: Candida albicans Fig. 2 from Brothers et al., 2011
neutrophil migration decreased occurrence, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil migration decreased process quality, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil migration decreased process quality, abnormal transection: caudal fin, chemical treatment by environment: isopimpinellin Fig. 2 with image from Robertson et al., 2016
neutrophil migration process quality, abnormal chemical treatment by environment: inhibitor, amputation: caudal fin Fig. 1 with image from Ke et al., 2017
neutrophil migration process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 6 from Burgon et al., 2014
neutrophil migration process quality, abnormal physical alteration: anatomical structure, chemical treatment: pharmaceutical Fig. 3Fig. 4Fig. 5Fig. 6 from Burgon et al., 2014
neutrophil migration process quality, normal bacterial treatment by exposure to environment: Pseudomonas aeruginosa Fig. 1 with image from Díaz-Pascual et al., 2017
notochord neutrophil increased amount, abnormal bacterial treatment by injection: Escherichia coli K-12 Fig. 7 with image from Nguyen-Chi et al., 2014
phagocytosis process quality, normal fungal treatment by injection: Candida albicans Fig. 2 from Brothers et al., 2011
regenerating fin neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 2 with imageFig. 7 with image from Hoodless et al., 2016
regenerating fin neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by environment: alvocidib Fig. 2 with image from Hoodless et al., 2016
regenerating fin neutrophil chemotaxis occurrence, normal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 2 with image from Hoodless et al., 2016
regenerating fin neutrophil chemotaxis occurrence, normal transection: caudal fin, chemical treatment by environment: alvocidib Fig. 2 with image from Hoodless et al., 2016
regeneration epithelium neutrophil decreased amount, abnormal transection: caudal fin Fig. 6 with image from Robertson et al., 2016
regeneration epithelium neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by injection: nedocromil Fig. 6 with image from Robertson et al., 2016
regeneration epithelium neutrophil decreased amount, abnormal transection: caudal fin, chemical treatment by environment: isopimpinellin Fig. 2 with imageFig. 3 with image from Robertson et al., 2016
skeletal muscle neutrophil increased amount, abnormal viral treatment by injection: unidentified influenza virus Fig. 4 with image from Goody et al., 2017
skeletal muscle cell degenerate, abnormal viral treatment by injection: unidentified influenza virus Fig. 4 with image from Goody et al., 2017
skeletal muscle cell detached from skeletal muscle cell, abnormal viral treatment by injection: unidentified influenza virus Fig. 4 with image from Goody et al., 2017
trunk neutrophil increased amount, abnormal chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid Fig. 1 from Oehlers et al., 2017
whole organism decreased life span, abnormal fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone Fig. 2 from Inglesfield et al., 2018
whole organism gbp4 expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
whole organism cxcl8b.1 expression increased amount, abnormal chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8b.1 expression increased amount, abnormal chemical treatment by environment: poly(I:C) Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8b.1 expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8b.1 expression increased amount, abnormal viral treatment by exposure to environment: Carp sprivivirus Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal chemical treatment by environment: poly(I:C) Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal chemical treatment by environment: double-stranded DNA Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal viral treatment by exposure to environment: Carp sprivivirus Fig. 1 from de Oliveira et al., 2015
whole organism cxcl8a expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from de Oliveira et al., 2015
whole organism il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
whole organism neutrophil amount, normal transection: caudal fin, chemical treatment by environment: alvocidib Fig. 2 with image from Hoodless et al., 2016
whole organism neutrophil amount, normal transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Fig. 2 with image from Hoodless et al., 2016

CITATIONS  (123)